A novel vaccine based on SARS-CoV-2 CD4⁺ and CD8⁺ T cell conserved epitopes from variants Alpha to Omicron.

ABSTRACT: COVID-19 caused, as of September, 1rst, 2022, 599,825,400 confirmed cases, including 6,469,458 deaths. Currently used vaccines reduced severity and mortality but not virus transmission or reinfection by different strains. They are based on the Spike protein of the Wuhan reference virus, which although highly antigenic suffered many mutations in SARS-CoV-2 variants, escaping vaccine-generated immune responses. Multiepitope vaccines based on 100% conserved epitopes of multiple proteins of all SARS-CoV-2 variants, rather than a single highly mutating antigen, could offer more long-lasting protection. In this study, a multiepitope multivariant vaccine was designed using immunoinformatics and in silico approaches. It is composed of highly promiscuous and strong HLA binding CD4⁺ and C

SUBMITTER: Palatnik-de-Sousa I 

PROVIDER: S-EPMC9537284 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature